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SUMMARY
Miltefosine was investigated for its activity against Neospora caninum tachyzoites in vitro, and was shown to inhibit the
proliferation ofN. caninum tachyzoites cultured in human foreskin ﬁbroblasts (HFF) with an IC50 of 5·2 μM. Treatment of
infected cells with 25 μM miltefosine for a period of 10 h had only a parasitostatic eﬀect, while after 20 h of treatment
parasiticidal eﬀects were observed. This was conﬁrmed by transmission electron microscopy of N. caninum-infected and
miltefosine-treated HFF. Administration of miltefosine to N. caninum-infected Balb/c female mice at 40mg/kg/day for
14 days resulted in 6 out of 10 mice exhibiting weight loss, ruﬄed coat and apathy between days 7 and 13 post-infection. In
the group that received placebo, only 2 out of 8 mice succumbed to infection, but the cerebral burden was signiﬁcantly
higher compared to the miltefosine treatment group. In a second experiment, the time-span of treatment was reduced to
5 days, and mice were maintained without further treatment for 4 weeks. Only 2 out of 9 mice in the miltefosine treatment
group exhibited signs of disease, while 8 out of 10 mice succumbed to infection in the placebo group. These results showed
that miltefosine hampered the dissemination of parasites into the CNS during experimental N. caninum infection in mice.
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INTRODUCTION
Neospora caninum, an apicomplexan parasite that was
initially described associated with severe neuromus-
cular disease in dogs (Dubey et al. 1988), represents
one of the most important causative agents of
infectious bovine abortion. Neosporosis is respon-
sible for important economic loss in both dairy and
beef cattle worldwide, also involving reduced milk
yield and diminished post-weaning weight gain in
beef calves (Dubey et al. 2007; Dubey and Schares,
2011). The worldwide serious economic impact of
neosporosis upon the cattle industry has inﬂamed
the interest for an eﬀective control strategy as
well as for prophylactic or metaphylactic measures
to prevent and treat bovine neosporosis infection. At
the present time, there is no vaccine available to
induce complete protective immunity (Monney et al.
2011). Therefore, chemotherapeutic measures using
pharmacologically active compounds might rep-
resent economically viable options, provided that
suitable compounds are identiﬁed (Häsler et al.
2006a,b).
To date, no speciﬁc treatment against neosporosis
is available. However, several studies on chemother-
apeutically interesting compounds have been carried
out. These include lasalocid, monensin, pirithrexim,
pyrimethamine, clindamycin, robenidine and
trimethoprim (Lindsay et al. 1994), artemisinin
(Kim et al. 2002), depudecin (Kwon et al. 2003),
toltrazuril, ponazuril (Darius et al. 2004), nitro-and
bromo-thiazolides (Esposito et al. 2005; 2007a,b),
pentamidine analogues (Leepin et al. 2008; Debache
et al. 2011) and alcoholic herbal extracts (Youn et al.
2004). Only few compounds have been investigated
for anti-Neospora activity using experimental in vivo
models. A low eﬃcacy inNeospora-infected mice was
reported for sulfadiazine and amprolium (Lindsay
and Dubey, 1990). Toltrazuril, a triazinone derivate
that inhibits the electron transfer in the mitochon-
drial respiratory chain, was shown to exhibit eﬀective
anti-parasitic activity against N. caninum in mice
(Gottstein et al. 2001), while results in bovines
did not allow deﬁnitive conclusions (Kritzner et al.
2002; Haerdi et al. 2006). Arylimidamides also seem
to be interesting compounds for chemotherapeutical
intervention. For instance, DB750, a phenylated
pentamidine analogue, signiﬁcantly improved the
survival rate and reduced the cerebral parasite
burden in experimentally infectedmice when applied
intraperitoneally. In contrast, nitazoxanide, which
had shown promising activity against N. caninum in
vitro, was not active in vivo, (Debache et al. 2011).
Miltefosine (hexadecylphosphocholine, HePC) is
an alkylphospholipid originally developed as an anti-
cancer agent for local treatment of skin metastases. It
was later found to showpotent leishmanicidal activity
as a consequence of its interference in the parasite’s
metabolic pathways (Unger et al. 1989; Barratt et al.
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2009). Miltfosine is commercialized in Germany as
Impavido(R) for leishmaniasis treatment, is also
registered for the treatment of visceral and cutaneous
leishmaniasis in India and Colombia, and is under-
going clinical trials for registration in several other
countries, including Brazil and Guatemala. It cur-
rently represents the only eﬀective oral treatment
for leishmaniasis. The mode of action of miltefosine
against Leishmania parasites involves the interaction
with membrane phospholipids and sterols, and the
drug interferes with the functionality of a number
of enzymes involved in phospholipid metabolism
such as protein kinase C and the phospholipases A, C
and D, ﬁnally leading to apoptosis (Barratt et al.
2009). Hexadecyltrimethylammonium bromide, a
compound structurally similar to miltefosine, was
demonstrated to exhibit potent in vitro activity
against Plasmodium falciparum (Walochnik et al.
2002; Schuster et al. 2006; Choubey et al. 2007).
In this study, we investigated the eﬀects of
miltefosine against N. caninum tachyzoites in cul-
tured ﬁbroblasts. In experimentally infected mice,
miltefosine treatment at 40mg/kg/day for 17 days
aﬀected the disseminiation of the parasite into the
CNS, but 50% of the mice succumbed to infec-
tion, indicating that miltefosine treatment rendered
mice more susceptible to neosporosis. However,
reducing the treatment time to 5 days severely
inhibited N. caninum dissemination and cerebral
infection.
MATERIALS AND METHODS
Unless otherwise stated, cell culture reagents were
supplied by Gibco-BRL (Zürich, Switzerland) and
chemicals were purchased from Sigma (St Louis,
MO, USA).
Cell culture and Neospora caninum puriﬁcation
Vero cells (green monkey kidney epithelial) and
human foreskin ﬁbroblasts (HFF) were routinely
cultured in RPMI 1640 medium supplemented with
10% heat-inactivated FCS, 2mM glutamine, 50U of
penicillin/ml and 50 μg of streptomycin/ml at 37 °C/
5% CO2 in tissue-culture ﬂasks. Cultures were
passaged at least once per week. N. caninum
tachyzoites of the Nc1 strain (Dubey et al. 1988)
were maintained by serial passages in Vero cells or
HFF during which time FCS was replaced with 5%
immunoglobulin G (IgG)-free horse serum (HS).
Parasites were harvested as described previously
(Hemphill, 1996). Infected cells were trypsinized,
washed twice in cold RPMI 1640 medium, and
the resulting pellet was re-suspended in 2ml of
cold RPMI 1640 medium. Cells were repeatedly
passaged through a 25 G-needle and liberated
tachyzoites were puriﬁed by passage through
Sephadex-G25 columns (Amersham Biosciences,
Otelﬁngen, Switzerland), previously equilibrated
with cold RPMI 1640 medium. Puriﬁed tachyzoites
were obtained after centrifugation at 600 g/10 min/4 °
C, and re-suspended in 1ml of RPMI 1640 contain-
ing 5% FCS, 50U of penicillin/ml and 50 μg of
streptomycin/ml. They were counted in a Neubauer
chamber and used to infect HFF monolayers as
described below.
In vitro miltefosine treatments
In vitro drug treatment assays were carried out in
triplicate essentially as described by Leepin et al.
(2008). HFF cell monolayers were grown to conﬂ-
uency in 24-well tissue-culture plates, and infec-
tion was carried out for 1 h by addition of 2×104 cell
culture-derived N. caninum tachyzoites per well.
Infected monolayers were washed 3 times with
cold RPMI 1640, and fresh medium was added,
containing miltefosine, previously prepared as a stock
solution in dimethyl sulfoxide (DMSO), at concen-
trations ranging from 0·1 μg/ml to 50 μg/ml. Controls
contained DMSO solvent alone. The cultures were
maintained for 72 h at 37 °C/5% CO2 and were
inspected daily by light microscopy. After 72 h the
medium was removed, and attached cells were
suspended in 200 μl of lysis buﬀer (Qiagen, Basel,
Switzerland) and stored at −20 °C for subsequent
N. caninum real-time PCR analysis (Müller et al.
2002).
IC50 values were calculated after logit–log-
transformation of the relative growth data (RG;
control = 1) according to the formula ln[(RG/(1 −
RG)]=a×ln(drug concentration)+b. Subsequent
regression analysis was performed using the corre-
sponding software tool contained in the Excel soft-
ware package (Microsoft, Seattle, WA, USA).
To determine the time-span required for miltefo-
sine to exert a true parasiticidal activity, infected
HFF monolayers were treated with 25 μM milte-
fosine (5 times IC50) for 10 h or 20 h. The drug-
containing medium was then removed and replaced
with fresh culturemediumwithout drug and changed
every 2 days. Samples were collected on a daily basis
by adding 200 μl of Lysis buﬀer (Qiagen, Basel,
Switzerland) until up to 9 days post-treatment and
stored at−20 °C for subsequentN. caninum real-time
PCR analysis.
Transmission electron microscopy (TEM)
HFF cell layers were grown to conﬂuency in Corning
cell-culture ﬂasks, infected with N. caninum tachy-
zoites for 2 days and treated with miltefosine at
24·5 μM. After 10 h or 20 h, respectively, samples
were rinsed with sterile PBS, washed in 100mM
sodium cacodylate buﬀer (pH 7·2), and ﬁxed in
cacodylate buﬀer containing 2·5% glutaraldehyde
for 2 h at room temperature. Cells were scraped
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with a rubber policeman and centrifuged at 1000 g
for 10min at 4 °C and, and the resulting pellet
was further ﬁxed at 4 °C overnight, followed by
post-ﬁxation in 2% OsO4 in cacodylate buﬀer for 4 h
at 4 °C. Subsequently, specimens were washed in
water and pre-stained in 1% uranyl acetate in water
for 1 h at 4 °C, followed by extensive washing in
water. Following dehydration in a graded series of
ethanol (30, 50, 70, 90, and 100%), they were
embedded in Epon 820 epoxy resin over a period
of 2 days with 3 resin changes. The resin was
polymerized at 65 °C for 24 h. Ultrathin sections
were cut on a Reichert and Jung ultramicrotome
and were loaded onto 300-mesh copper grids
(Plano GmbH, Marburg, Germany). Staining with
uranyl acetate and lead citrate was performed as
described by Leepin et al. (2008).
In vivo Experiment 1: long-term miltefosine treatments
in Neospora caninum-infected Balb/c mice
Female Balb/c mice (6 weeks of age) were purchased
from Charles River Laboratories (Sulzheim,
Germany) and housed under conventional day/
night conditions according to the standards set up
by the animal welfare legislation of the Swiss
Veterinary Oﬃce. At the age of 8–9 weeks, mice
were randomly divided into 4 groups of 8 or 10 mice
each (Table 1) and the serological status (Neospora-
negative) was checked by enzyme-linked immuno-
sorbent assay (ELISA). Miltefosine suspensions
were prepared in 0·5% carboxy-methylcellulose
(CMC) at 20 and 40mg/kg/day, respectively, con-
trols received CMC without drug. The drug and
control suspensions were sterile ﬁltered and applied
by intragastric inoculation (100 μl per mouse/day).
At days 1–3, all mice received the corresponding dose
ofmiltefosine or CMC, at day 4 all micewere infected
intraperitoneally with freshly puriﬁed N. caninum
tachyzoites (2×106) resuspended in 100 μl RPMI,
with the exception of the group receiving miltefosine
40mg/kg/day without infection (see Table 1).
Treatments were continued until 14 days post-
infection (p.i.). Mice were weighed daily to assess
potential toxicity. Animals exhibiting signs of acute
disease (ruﬄed coat/inability to reach up for food
and water/apathy) or neuronal symptoms (head tilt,
running in circles, hind limb paralysis) were eu-
thanized at the onset of these symptoms. Latest
on day 18 p.i., all mice were sacriﬁced by CO2-
euthanasia. Brains were collected using individual
sterile instruments and immediately frozen at−20 °C
for subsequent quantitative PCR analysis.
In vivo Experiment 2: short-term miltefosine
treatments in Neospora caninum-infected Balb/c mice
Female mice (Charles River Laboratories, Sulzheim,
Germany) were housed under conditions as described
above, and were divided into 2 groups of 10 (placebo)
and 9 (miltefosine, 40mg/kg/day), respectively.
Treatments and infection were done as described
above, but miltefosine treatment was discontinued
at day 5 p.i., and mice were observed for another 30
days. Animals exhibiting signs of disease were
euthanized at the onset of these symptoms and on
day 35 p.i. at the latest, all mice were sacriﬁced by
CO2-euthanasia. Collection of tissue samples and
storage was done as for Experiment 1
DNA extraction and real-time-PCR
DNA puriﬁcation from in vitro cultures and cerebral
tissues was performed using the DNeasy® Blood &
Tissue Kit (Qiagen, Basel, Switzerland) according
to the standard protocol suitable for animal
tissues. Frozen samples were lysed overnight at 56 °
C in 1ml of ATL buﬀer containing proteinase K,
and 100 μl of the suspension were used for
DNA puriﬁcation. DNA was eluted in 50 μl of AE
buﬀer and boiled at 95 °C. The DNA concentrations
in all samples were determined by UV spectropho-
tometry and adjusted to 100 ng/μl with sterile
DNAse-free water. The assessments of N. caninum
tachyzoite loads were performed using a
LightCycler™ Instrument (Roche Diagnostic, Basel,
Switzerland) as previously described (Cannas et al.
2003a,b; Alaeddine et al. 2005; Debache et al. 2009).
The parasite counts were calculated by interpolation
from a standard curve with DNA equivalents from
1000, 100 and 10 parasites included in each run.
Statistical analysis
The signiﬁcance of the diﬀerences between values
of the control and experimental assays in parasite
load assessment in vitro assay was determined by
Student’s t-test using the Microsoft Excel program.
P values of <0·01 and <0·05 were considered
statistically signiﬁcant. Cerebral parasite loads in
diﬀerent treatment and control groups were analysed
by Tukey-Kramer Multiple-Comparison (P<0·05).
To determine the signiﬁcance of mean weight loss
prior and after treatment in the diﬀerent experimen-
tal groups, one-way ANOVA followed by Duncan’s
multiple range test were employed.
RESULTS
In vitro activity of miltefosine in HFF and Vero cells
In order to investigate potential susceptibility of the
host cells used for culture of N. caninum tachyzoites,
namely Vero cells and HFF, respectively, non-
infected conﬂuent monolayers were incubated with
diﬀerent concentrations of miltefosine (1·5–122 μM)
for 48 h, and cultures were stained with Trypan blue.
Light microsocpical inspection revealed that miltefo-
sine had no eﬀect onHFFmonolayers, whileVero cell
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monolayers contained numerous (up to 50%) Trypan
blue positive cells even at the lowest miltefosine
concentration used (data not shown). Thus, HFF
monolayers were used for further assessments on the
eﬀects of miltefosine againstN. caninum.
In vitro activity of miltefosine against Neospora
caninum tachyzoites
Diﬀerent concentrations of miltefosine (1·5–122 μM)
were added toN. caninum-infectedHFFmonolayers,
and N. caninum proliferation was analysed after
3 days. Miltefosine inhibited the multiplication of
tachyzoites with an IC50 of 5·2 μM, and parasite
proliferation was completely abolished at 50 μM
miltefosine (Fig. 1A).
Subsequently, infected cells were treated with
25 μM miltefosine for 10 h and 20 h, respectively
and, after washing in medium, cultures were main-
tained for an additional 9 days (Fig. 1B). A pro-
nounced inhibition of parasite proliferation was
observed in both treatment groups during a period
of 3 days following treatment. Subsequently, tachy-
zoites in those cultures treated for 10 h resumed
proliferation. In contrast, in those specimens treated
for 20 h the numbers of tachyzoites decreased
continuously until day 9, indicating that in this case
miltefosine exhibited parasiticidal eﬃcacy.
Eﬀects of miltefosine treatment on the ultrastructure of
Neospora caninum tachyzoites
The morphological and structural alterations associ-
ated with miltefosine treatments in N. caninum-
infected HFF were visualized by TEM. In
non-treated control cultures, intact N. caninum
tachyzoites were localized within a parasitophorous
vacuole, surrounded by a parasitophorous vacuole
membrane, and characteristic organelles such as
micronemes, rhoptries and dense granules, were
clearly identiﬁed (Fig. 2A). Upon miltefosine treat-
ment of infected cultures for 10 h, prominent
alterations were noted within the tachyzoite cyto-
plasm, such membrane stacks and an increasing
Fig. 1. Eﬀects of miltefosine on the proliferation of Neospora caninum tachyzoites in HFF monolayers in vitro. (A)
Dose-dependent inhibition of tachyzoite proliferation in HFF. The experiment was carried out in triplicate for each
concentration and results are presented as means of number of tachyzoites±S.D. Asterisks indicate those parasite
numbers signiﬁcantly diﬀering from the parasite as assessed in the infection control (0 μg/ml) (P<0·01). (B) Parasiticidal
eﬃcacy of miltefosine against N. caninum tachyzoites proliferation. Miltefosine (25 μM) was applied for 10 h and 20 h
respectively, cultures were washed and further incubated in medium for up to 9 days. From day 6 onwards, all parasite
numbers assessed from 20 h post-treatment samples were signiﬁcantly lower compared to tachyzoite numbers in the
infection control and the 10 h post treatment samples. Results are presented as means of number of tachyzoites±S.D.
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Fig. 2. TEM of Neospora caninum tachyzoites grown in HFF. (A) Non-treated control culture, with tachyzoites within
a parasitophorous vacuole that is delineated by a parasitophorous vacuole membrane (pvm). The hallmarks of
apicomplexan parasites such as rhoptries (rop), micronemes (mic) and dense granules (dg) are clearly visible. AE,
anterior end; con, cross-section through a conoid; nuc, nucleus. Scale bar=0·32 μm. (B) TEM after treatment of infected
monolayers with 25 μM miltefosine for 10 h. Note the presence of an apoptotic body (ab) in one tachyzoite, membrane
stacks are indicated by 2 thin horizontal arrows, increased vacuolization is indicated by thick arrows, ld, lipid droplets;
pm, plasma membrane. Scale bar=0·38 μm.
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number of vacuoles within the parasite cytoplasm,
some of which were ﬁlled with membranous and
granular material of unknown origin, electron-dense
inclusions, and the presence of structures resembling
apoptotic bodies in some parasites (Fig. 2B). In
addition, lipid droplets formed in the close vicinity
of the parasitophorous vacuoles, although clearly
localized within the cytoplasm of the host cells
(Fig. 2B). Such lipid droplets were not found in
uninfected ﬁbroblasts (not shown). Upon incubation
of infected cultures with miltefosine for 20 h, the
alterations became much more pronounced. Most
host cells harboured remnants of parasitophorous
vacuoles that were ﬁlled with a dense granular matrix,
containing completely distorted tachyzoites, and the
micronemes, rhoptries and dense granule organelles
werenot discernible anymore.Theparasite cytoplasm
was lacking any distinct subcellular organization;
however, in all cases the parasitemembrane surround-
ing the tachyzoites still appeared to be intact (Fig. 3A,
B). Few tachyzoites were found that were still
localized within a parasitophorous vacuole sur-
rounded by a distinct parasitophorous vacuole mem-
brane, but they also contained vacuoles ﬁlled with
membrane stacks and other unidentiﬁedmaterial, and
large lipid droplet were localized just adjacent to the
parasitophorous vacuole membrane (Fig. 3C). Many
liberated, but clearly distorted tachyzoites were
identiﬁed in the extracellular space, often surrounded
by cellular debris of unknown origin (Fig. 3D). Thus,
miltefosine treatment had a profound eﬀect on the
ultrastructure ofN. caninum tachyzoites.
Fig. 3. TEM of Neospora caninum tachyzoites grown in HFF and treated with 25 μMmiltefosine for 20 h. (A)
Overview and (B) corresponding higher magniﬁcation view of 2 intracellular tachyzoites. Parasites are largely
surrounded by a parasitophorous vacuole (pvm), and embedded in a dense granular matrix. Thick arrows indicate
extensive vacuolization, con, conoid. Scale bar in (A)=8 μm; in (B)=0·4 μm. (C) Intracellular tachyzoite with alterations
such as cytoplasmic membrane stacks (horizontal arrows), still intact plasma membrane (pm) and parasitophorous
vacuole membrane (pvm), and lipid droplets (ld) just adjacent to the pvm; dg, dense granules. Scale bar=0·38 μm.
(D) Extracellular, non-viable tachyzoite with distorted cytoplasmic organization, containing apoptotic body (ab), lipid
droplet (ld) and cytoplasmic vacuoles ﬁlled with material of unknown origing (thick arrow). The plasma membrane still
appears intact (pm). Scale bar=0·38 μm.
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Miltefosine treatment in mice experimentally infected
with Neospora caninum tachyzoites
In Experiment 1, miltefosine was orally applied to
N. caninum-infected Balb/c mice at 20 and 40mg/kg/
day for a period of 14 days p. i., respectively, a
placebo control group received PBS/CMC only, and
a fourth group remained uninfected and was treated
with 40mg/kg/day of miltefosine to assess a poten-
tial impact of medication on the health of the ani-
mals. After the 14 days treatment period, mice were
euthanized and the cerebral parasite burden was
assessed. In the placebo group, 2 out of 8 mice
succumbed to infection at days 11 and 12 p.i., while
in the group treated with miltefosine at 20mg/kg/day
1 mouse died at day 12 p.i. No signiﬁcant average
weight loss was recorded during the 14 days of
treatment (Table 1). Comparison of the cerebral
parasite load in the 2 groups did not reveal any major
diﬀerences (Fig. 4A, Supplementary Table 1, online
version only). However, when N. caninum-infected
mice were treated with 40mg/kg/day of miltefosine,
6 out of 10 mice exhibited ruﬄed coat, general
weakness and apathy, and they were not able to feed
anymore. Thus they had to be euthanized at the onset
of these symptoms between days 7 and 13 p.i.. None
of the mice exhibited neurological disorders such as
tilting and hind limb paralysis. In addition, a
signiﬁcant mean weight loss of over 10% was noted
for that group within that 14-day period. Application
of miltefosine at 40mg/kg/day in non-infected mice,
however, did not result in any weight loss or signs
of toxicity, indicating that the drug per se did not
exert any toxic eﬀects (Table 1). Mice treated with
40mg/kg/day for 14 days exhibited signiﬁcantly
lower cerebral parasite burdens compared to the
placebo group (Fig. 4A). This result suggested that
miltefosine treatment, although not causing any
harm by itself, rendered mice more susceptible to
acuteN. caninum infection, and the cause of death of
these animals was due to infection of other organs.
In Experiment 2, N. caninum-infected mice were
treated with 40mg/kg/day, but only for a period of
5 days p.i., and were then left untreated for 30 days.
As indicated in Table 1, miltefosine treatment had
a profound impact, with only 2 out of 9 mice
succumbing to infection on days 5 (due to weakness
and apathy) and 26 (neurological signs such as head
tilt and running in circles), respectively. On the other
hand, 8 out of 10 mice had to be euthanized in the
placebo group between days 16 and 31. These mice
exhibited neurological symptoms (head tilt, hind
limb paralysis, circular movements, ruﬄed coat),
indicative for CNS involvement. The overall cerebral
parasite burden in the miltefosine-treated mice was
signiﬁcantly lower compared to the placebo group
(Fig. 4B, Supplementary Table 1, online version
only). This showed that the drug inhibited the
proliferation of N. caninum and dissemination of
tachyzoites into the cerebral tissue.
DISCUSSION
Miltefosine, originally developed as an anti-cancer
agent, is used for the treatment of skin metastases
of mammacarcinoma (Leonard et al. 2001).
Subsequently it was found that miltefosine is also
Table 1. In vivo studies: summary of experimental groups and outcome of experiments in terms of
symptomatic mice, time of death and median body weights at day 0 and at the end of the experiments, day
14 for Exp. 1 and day 30 for Exp. 2
(Signiﬁcant weight loss is found only in the experimentally infected mice treated with miltefosine (40mg/kg/day for 14
days) and indicated by *.)
Groups Number of mice
Number of
sympt.
mice
Time of
death
(days p.i.)
Weight at day p.i.
0 14 or 30
E
xp
er
im
en
t
1
Non-infected miltefosine
40mg/kg/day 14 days
8 – – 18·95±0·80 18·86±0·56
Infected placebo CMC
only 14 days
8 2 11/12 19·07±0·99 18·18±0·56
Infected miltefosine
20mg/kg/day 14 days
8 1 12 17·9±0·92 17·3±1·59
Infected miltefosine
40mg/kg/day 14 days
10 6 7/10/11/12/12/13 20·09±0·73 17·47±1·52*
E
xp
er
im
en
t
2 Placebo CMC only 5 days 10 8 16/19/22/22/25/26/
27/31
19·5±0·86 18·9±0·42
Miltefosine 40mg/kg/day
5 days
9 2 5/26 18·85±0·82 18·41±0·61
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active against visceral and cutanous leishmaniasis,
and can be applied orally or topically, respectively
(Croft and Engel, 2006; Bhattacharya et al. 2007).
The drug was also active against Trypanosoma brucei,
Entamoeba histolytica, Acanthamoeba spp. and T.
cruzi (Croft et al. 1996; Konstantinov et al. 1997;
Seifert et al. 2001; Walochnik et al. 2002), and it was
shown thatmiltefosine aﬀects apicomplexan parasites
such as Plasmodium falciparum and Cryptosporidium
(Pessi et al. 2004; Shahiduzzaman et al. 2009).
Similar to many of the above-mentioned protozoan
parasites, Neospora occupies an intracellular niche,
indicating that miltefosine might also be useful for
the treatment neosporosis.
In vitro cytotoxicity assays demonstrated that Vero
cells, which represent an immortalized and highly
proliferative cell line that does not undergo contact
inhibition, are highly susceptible to the drug. In
contrast, human foreskin ﬁbroblasts, which do not
proliferate further once a conﬂuent monolayer is
formed, were not aﬀected by miltefosine treatment
at concentrations up to 122 μM.This reﬂects the anti-
proliferative properties of miltefosine (Leonard et al.
2001). The drug inhibited the proliferation of
N. caninum tachyzoites with an IC50 of 5·2 μM,
which is in a similar range to that reported for
the thiazolide nitazoxanide (IC50=4·23 μM;
Esposito et al. 2007a), but substantially higher
than the dicationic pentamidine derivative DB750
(IC50=0·23 μM; Leepin et al. 2008). Miltefosine
appeared to act swiftly: at 25 μMan incubation period
of 20 h was suﬃcient to exert a parasiticidal activity
within N. caninum-infected HFF. In comparison,
nitazoxanide added to infected HFF at 30 μM
required a treatment duration of 5 days in order
to exert parasiticidal activity in vitro (Esposito et al.
2005), and for toltrazuril, a 10-day treatment at a
concentration of 70·5 μM had only a parasitostatic
eﬀect, and a total of 14 days were required to exert a
parasiticidal eﬀect (Strohbusch et al. 2009).
Toltrazuril (Darius et al. 2004), nitazoxanide and
other thiazoides (Esposito et al. 2005, 2007a, b), and
DB750 (Leepin et al. 2008), exerted profound
ultrastructural changes in N. caninum tachyzoites
in vitro. The same accounted for miltefosine in this
study. While we could not detect any major
diﬀerences between treated and untreated uninfected
HFF monolayers (data not shown), clear signs of
N. caninum tachyzoite deterioration were already
detectable after 10 h of treatment, which included
profound alterations in the organization of some of
the membrane-based compartments of the cyto-
plasm. Rhoptries and micronemes were mostly no
longer visible after 10 h of treatment, while the
electron-dense granules were apparently aﬀected by
a lower degree, and in many cells rounded structures
resembling apoptotic bodies were evident. The
tachyzoite cytoplasm exhibited increased vacuoliza-
tion but, in most cases, no damage could be detected
on nuclear membranes and parasite plasma mem-
branes. In several tachyzoites layers of membrane
stacks localized near the parasite nucleus were
observed. An impressive number of lipid droplets
accumulated within the host cell cytoplasm in close
vicinity of the parasitophorous vacuole membrane.
After 20 h of miltefosine treatment, the majority
of tachyzoites were found either intracellularly,
obviously non-viable and often embedded in a rather
electron-dense granular matrix ﬁlling the parasito-
phorous vacuole, or were present in the extracellular
space, without any clearly discernible organized
Fig. 4. Box plots showing the eﬀects of miltefosine
treatments on the cerebral parasite burden in mice
experimentally infected with Neospora caninum
tachyzoites. (A) Treatment with miltefosine (20 or 40mg/
kg/day for 14 days) or placebo. The y-axis depicts the
number of detected parasites by real time PCR /100 ng
of DNA. The placebo group was treated identically but
with the solvent carboxy-methylcellulose (CMC) only.
* Indicates a signiﬁcant reduction in parasite load
(P<0·05). (B) Treatment with miltefosine (40mg/kg/day)
for a period of 5 days p.i. only, followed by maintenance
of mice for 30 days without treatment. * Indicates a
signiﬁcant reduction in parasite load (P<0·05) in the
treatment group. For more details on cerebral parasite
burden of each individual mouse refer to supplementary
Table 1, online version only.
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cytoplasmic features, with the exception of lipid
droplets. For the parasites located intracellularly, the
electron-dense parasitophorous vacuolar matrix clo-
sely resembled the cyst-wall associated structures
observed during in vitro development of N. caninum
bradyzoites induced by sodium nitroprusside treat-
ment (Vonlaufen et al. 2002, 2004). This matrix
could be formed due to stress-related increased
secretory activity, most notably from the parasite
dense granule organelles (Vonlaufen et al. 2004). The
presence of extracellular tachyzoites could be a result
of increased, drug-induced egress and the inability of
the parasite to subsequently invade another host cell
successfully, as has previously been demonstrated for
a series of thiazolides (Esposito et al. 2007a).
The presence of increased numbers of lipid
droplets within the host cell and tachyzoite cytoplasm
could be caused by disturbances in fatty acid
and sterol metabolism as previously reported for
L. donovani by Rakotomanga et al. (2007). It is not
clear whether the increased presence of lipid droplets
in the vicinity of parasitophorous vacuoles reﬂects
a similar eﬀect in host cells, or whether they are a
consequence of stress that is induced by the presence
of tachyzoites. More prolonged TEM investigations
covering more time-points would be required to
study the eﬀects of deteriorating parasites on host cell
survival. Similar studies undertaken with nitazox-
anide and related compounds (Esposito et al. 2005)
had suggested that parasite death also had a negative
impact on host cell ultrastructure and survival.
However, in specimens incubated with miltefosine
for 20 h, the vast majority of observed tachyzoites
exhibited a clearly discernible plasma membrane,
which would be indicative of apoptotic events taking
place during drug treatment. This would be in
accordance with previous studies on L. donovani
(Paris et al. 2004).
Perez-Victoria et al. (2006) had reported that
uptake of miltefosine is mediated by a plasma
membrane P-type ATPase aminophospholipid trans-
locase. Suggested targets of miltefosine inLeishmania
include perturbation of ether-lipid metabolism,
glycosylphosphatidylinositol (GPI) anchor biosyn-
thesis and signal transduction as well as inhibition of
the glycosomal located alkyl-speciﬁc acyl-Co-A
acyltransferase, an enzyme involved in lipid remodel-
ling (Lux et al. 2000). However, more detailed
investigations are required in order to deﬁne the
mechanisms that account for the eﬀects of miltefosine
against N. caninum tachyzoites.
The relatively low host cell toxicity and clear
parasiticidal activity in vitro prompted us to under-
take an in vivo study on the eﬀects of miltefosine
treatment on Neospora infection in mice. A ﬁrst set
of experimental groups were treated with either
20mg/kg/day or 40mg/kg/day for a period of 14
days, after which the animals were euthanized and
analysed, similar to previous studies employing the
dicationic compound DB750 (Debache et al. 2011).
The goal was to investigate whether miltefosine
aﬀected cerebral infection. Our results show that in
N. caninum-infected mice treatment with miltefosine
at 20mg/kg/day did not reduce the cerebral parasite
burden compared to the placebo group, while
treatment at 40mg/kg/day did, but those mice
could obviously not cope with the infection. In
human patients, adverse side eﬀects of miltefosine
treatment have been reported such as vomiting,
nausea, kinetosis, headache, diarrhoea, and a mild
to moderate increase in aminotransferases and crea-
tinine (reviewed by Oliveira et al. 2011). In contrast,
application of miltefosine at 40mg/kg/day for only 5
days did not exert any adverse eﬀects. Following
treatment, mice were monitored for a period of 30
days, and subsequent analysis showed a signiﬁcantly
reduced number of fatalities and a signiﬁcantly
decreased cerebral parasite burden in the miltefosine
treatment group. When used for the treatment of
Leishmania parasites in Balb/c mice, miltefosine
treatment for 5 consecutive days at 30mg/kg/day
was highly eﬀective, as was the case when treatment
was performed in Leishmania-infected scid mice
(Escobar et al. 2001).
The results obtained inN. caninum infected Balb/c
mice suggest that miltefosine treatment can limit
the dissemination of tachyzoites into the CNS.
However, further studies are needed to demonstrate
the potential of this compound in cases where the
CNS has already been invaded by the parasite. Since
miltefosine is an amphipatic molecule, it is likely to
cross the blood-brain barrier, and further studies will
show whether miltefosine can also exert an eﬀect
against parasites within the CNS. Since this drug is
already in use for the treatment of canine leishma-
niasis, its application in cases of canine neosporosis
might be an attractive option.
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